5ʹ-Ectonucleotidase CD73/NT5E supports EGFR-mediated invasion of HPV-negative head and neck carcinoma cells

[1]  Yunyun Xu,et al.  Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma , 2022, Frontiers in Immunology.

[2]  F. Mungenast,et al.  Interplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC , 2022, Biomedicines.

[3]  U. Schumacher,et al.  A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer , 2022, Molecular cancer.

[4]  Bing Tao,et al.  NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment , 2022, Frontiers in Immunology.

[5]  Q. Cheng,et al.  Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts , 2022, Journal of Hematology & Oncology.

[6]  Liyi Xie,et al.  Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death , 2022, Journal of experimental & clinical cancer research : CR.

[7]  Rui-Lin Wang,et al.  CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway , 2022, BioMed research international.

[8]  G. Yegutkin,et al.  ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain , 2022, Pharmacological Reviews.

[9]  Ruixia Wang,et al.  CD73 facilitates invadopodia formation and boosts malignancy of head and neck squamous cell carcinoma via the MAPK signaling pathway , 2022, Cancer science.

[10]  G. Lenz,et al.  The crossroads of adenosinergic pathway and epithelial-mesenchymal plasticity in cancer. , 2022, Seminars in cancer biology.

[11]  Chi Thi Kim Nguyen,et al.  Comprehensive Integrated Single-Cell Whole Transcriptome Analysis Revealed the p-EMT Tumor Cells—CAFs Communication in Oral Squamous Cell Carcinoma , 2022, International journal of molecular sciences.

[12]  Ming Yan,et al.  CD73 in small extracellular vesicles derived from HNSCC defines tumour‐associated immunosuppression mediated by macrophages in the microenvironment , 2022, Journal of extracellular vesicles.

[13]  D. Gu,et al.  Head and Neck Squamous Cell Carcinoma: NT5E Could Be a Prognostic Biomarker , 2022, Applied bionics and biomechanics.

[14]  B. Vick,et al.  A Novel Anti-CD73 Antibody That Selectively Inhibits Membrane CD73 Shows Antitumor Activity and Induces Tumor Immune Escape , 2022, Biomedicines.

[15]  K. Politi,et al.  Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC , 2022, JCI insight.

[16]  Y. Kudo,et al.  The role of partial-EMT in the progression of head and neck squamous cell carcinoma. , 2022, Journal of oral biosciences.

[17]  K. Dong,et al.  CD73 Severed as a Potential Prognostic Marker and Promote Lung Cancer Cells Migration via Enhancing EMT Progression , 2021, Frontiers in Genetics.

[18]  T. Brabletz,et al.  Dynamic EMT: a multi‐tool for tumor progression , 2021, The EMBO journal.

[19]  Shau-Hsuan Li,et al.  CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma , 2021, Cancers.

[20]  O. Gires,et al.  SLUG‐related partial epithelial‐to‐mesenchymal transition is a transcriptomic prognosticator of head and neck cancer survival , 2021, Molecular oncology.

[21]  C. R. Leemans,et al.  Resection Margins in Head and Neck Cancer Surgery: An Update of Residual Disease and Field Cancerization , 2021, Cancers.

[22]  I. Tirosh,et al.  Decoupling epithelial-mesenchymal transitions from stromal profiles by integrative expression analysis , 2021, Nature Communications.

[23]  Erin L. Schenk,et al.  CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  M. Nees,et al.  CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer , 2021, Scientific Reports.

[25]  Alexander R. Pico,et al.  Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. , 2021, Cancer cell.

[26]  F. Lin,et al.  CD73 promotes cervical cancer growth via EGFR/AKT1 pathway , 2021, Translational cancer research.

[27]  Jing Wang,et al.  Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  Wei Tang,et al.  CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma , 2020, Journal of Hematology & Oncology.

[29]  A. Mäkitie,et al.  Hallmarks of cancer: Tumor budding as a sign of invasion and metastasis in head and neck cancer , 2019, Head & neck.

[30]  G. Viani,et al.  Evaluation of survival of patients with locally advanced head and neck cancer treated in a single center , 2019, Brazilian journal of otorhinolaryngology.

[31]  W. Guo,et al.  CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis , 2019, Journal of Hematology & Oncology.

[32]  G. Lenz,et al.  EMT-like process in glioblastomas and reactive astrocytes , 2019, Neurochemistry International.

[33]  C. Belka,et al.  High Expression of EpCAM and Sox2 is a Positive Prognosticator of Clinical Outcome for Head and Neck Carcinoma , 2018, Scientific Reports.

[34]  B. Lenarčič,et al.  EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers , 2018, PLoS biology.

[35]  C. Welz,et al.  Evaluation of margins in head and neck squamous cell carcinoma from the surgeon's perspective , 2018, Head & neck.

[36]  U. Cavallaro,et al.  CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells , 2018, Stem cell reports.

[37]  I. Tirosh,et al.  Single cell RNA-seq highlights a role for a partial EMT in head and neck cancer , 2018, Molecular & cellular oncology.

[38]  Ruud H. Brakenhoff,et al.  The molecular landscape of head and neck cancer , 2018, Nature Reviews Cancer.

[39]  B. Stuck,et al.  CD73 expression in lymph node metastases in patients with head and neck cancer , 2018, Acta oto-laryngologica.

[40]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[41]  R. Brakenhoff,et al.  Molecular Patterns and Biology of HPV-Associated HNSCC. , 2017, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[42]  U. Leser,et al.  Basal subtype is predictive for response to cetuximab treatment in patient‐derived xenografts of squamous cell head and neck cancer , 2017, International journal of cancer.

[43]  Wei Li,et al.  CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer , 2017, Molecular Cancer.

[44]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[45]  W. Lu,et al.  CD73 is associated with poor prognosis in HNSCC , 2016, Oncotarget.

[46]  L. De Cecco,et al.  Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab , 2016, Clinical Cancer Research.

[47]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[48]  R. Broaddus,et al.  Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. , 2015, The Journal of clinical investigation.

[49]  Deena M. A. Gendoo,et al.  CD73 is associated with poor prognosis in high-grade serous ovarian cancer. , 2015, Cancer research.

[50]  C. von Buchwald,et al.  Molecular profiling of tumour budding implicates TGFβ‐mediated epithelial–mesenchymal transition as a therapeutic target in oral squamous cell carcinoma , 2015, The Journal of pathology.

[51]  J. Gornbein,et al.  HPV-Positive Oropharyngeal Carcinoma , 2015, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[52]  Guangming Zhou,et al.  Ecto-5'-nucleotidase expression is associated with the progression of renal cell carcinoma. , 2015, Oncology letters.

[53]  Kevin P. White,et al.  Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes , 2014, Clinical Cancer Research.

[54]  X. Miao,et al.  NT5E and FcGBP as key regulators of TGF-1-induced epithelial–mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer , 2013, Cell and Tissue Research.

[55]  V. Kosma,et al.  Depth of invasion, tumor budding, and worst pattern of invasion: Prognostic indicators in early-stage oral tongue cancer , 2013, Head & neck.

[56]  Z. Ou,et al.  Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis , 2013, Clinical & Experimental Metastasis.

[57]  V. Budach,et al.  Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[58]  T. Whiteside,et al.  Increased Ectonucleotidase Expression and Activity in Regulatory T Cells of Patients with Head and Neck Cancer , 2009, Clinical Cancer Research.

[59]  B. Mack,et al.  CD44s and CD44v6 Expression in Head and Neck Epithelia , 2008, PloS one.

[60]  Z. Ou,et al.  Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells , 2008, Journal of Cancer Research and Clinical Oncology.

[61]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Jeffrey W. Smith,et al.  Gene expression profiling of tumor xenografts: In vivo analysis of organ‐specific metastasis , 2003, International journal of cancer.

[63]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[64]  B. Mack,et al.  CD 44 s and CD 44 v 6 Expression in Head and Neck Epithelia , 2008 .

[65]  S. Kruijff,et al.  Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. , 2021, Cancer letters.